| Document |
Document Title |
|
WO/2023/003464A1 |
The invention relates to the field of protein engineering and biocatalysis, in particular to methods for oxygenation of aliphatic alkenes and terpenes using bacterial enzymes. Provided is a method for oxyfunctionalization of a substrate ...
|
|
WO/2023/000170A1 |
Provided is a mouse monoclonal anti-human CD147 antibody or a single-chain variable fragment (scFv), comprising VH having the amino acid of SEQ ID NO: 4 and VL having the amino acid of SEQ ID NO: 5, or VH having the amino acid of SEQ ID ...
|
|
WO/2023/002952A1 |
The present invention relates to fusion proteins comprising a ligand binding domain, a protease cleavage site, and a ligand moiety. The fusion proteins of the invention comprise a ligand binding domain, a ligand moiety, and a protease cl...
|
|
WO/2023/284371A1 |
Provided in the present invention are a KHL polypeptide, and the use thereof in the preparation of a TABP-EIC cell. In addition, also provided in the present invention are a KHL polypeptide conjugate, a tumor-antigen-binding polypeptide ...
|
|
WO/2023/286694A1 |
There are said to be approximately five million people worldwide who suffer from inflammatory bowel diseases including ulcerative colitis and Crohn's disease, and the development of therapeutic agents is hoped for. In particular, the dev...
|
|
WO/2023/284380A1 |
Provided is a clinical application of cells as vectors for gene therapy. Exosomes are used as primary vectors to load RNAs required for treatment, autologous or allogeneic mature somatic cells having high clinical safety or precursor cel...
|
|
WO/2023/284053A1 |
A chimeric antigen receptor targeting mesothelin, and the use thereof. The chimeric antigen receptor comprises an extracellular region, a transmembrane region and an intracellular domain which are sequentially linked, wherein the extrace...
|
|
WO/2023/288296A1 |
Provided herein are chimeric hMPV/RSV F proteins. In some aspects, the chimeric hMPV/RSV F proteins exhibit enhanced conformational stability, enhanced thermostability, and/or increased expression. Methods are also provided for use of th...
|
|
WO/2023/284733A1 |
The present invention relates to the field of biomedicine, and provides a GITR/TGF-β dual-targeted fusion protein, a conjugate and pharmaceutical composition comprising same, and a use of the fusion protein or conjugate in the preparati...
|
|
WO/2023/284700A1 |
A novel chimeric receptor composition, a recombinant vector, a cell, and an application thereof. The novel chimeric receptor composition comprises a conventional chimeric antigen receptor (CAR), and an NKG2D chimeric receptor comprising ...
|
|
WO/2023/284684A1 |
A milk-derived polypeptide derivative and applications thereof in the preparation of a drug, a health product and a food additive for the prevention and treatment of obesity, belonging to the technical field of biomedicine. The present m...
|
|
WO/2023/286766A1 |
The present invention provides a polypeptide containing an amino acid sequence (region 1) that specifically binds to a constant site of an antibody and an amino acid sequence (region 2) that specifically binds to a nucleic acid.
|
|
WO/2023/284889A1 |
The present application relates to the field of genetic engineering, specifically to a CLD protein mutant and the use thereof. The CLD protein mutant is as shown in SEQ ID NO. 4. According to the present invention, cysteine at position 6...
|
|
WO/2023/283736A1 |
Homologous dimerization (HD) peptides are described having improved self-binding. The HD peptides may comprise an amino acid sequence having the reverse configuration compared to a corresponding naturally occurring HD peptide or comprise...
|
|
WO/2023/284471A1 |
The present invention relates to a novel polypeptide for specific recognition of a prostate cancer cell, and a derivative and the use thereof. The polypeptide is obtained by means of screening a phage-polypeptide library, can specificall...
|
|
WO/2023/286841A1 |
Provided are: a chimeric antigen receptor comprising a target antigen binding region, a transmembrane region and a signal transduction region, in which the transmembrane region contains, at the C-terminal thereof, a first polypeptide sel...
|
|
WO/2023/284822A1 |
Provided are conjugates of polypeptides comprising nanobody and FGF21 linked by a polypeptide linker. Further provided are conjugates of polypeptides comprising GLP-1, nanobody, and FGF21 linked by two polypeptide linkers respectively. P...
|
|
WO/2023/286059A1 |
Compositions and methods for treating a medical condition are provided. Accordingly, there is provided a composition comprising a polypeptide comprising a GnRH receptor binding protein and a polynucleotide coding a therapeutic agent, whe...
|
|
WO/2023/286840A1 |
An anti-EGFRviii antibody that is an antibody having a specific CDR sequence and is selected from the group consisting of the antibodies (a-1) to (a-3); a polypeptide comprising the antibody; a cell capable of expressing the polypeptide;...
|
|
WO/2023/288281A2 |
The present disclosure provides fusion proteins with novel signaling properties. Disclosed embodiments include fusion proteins that comprise an extracellular component that is capable of binding to a TGFβ polypeptide, a transmembrane co...
|
|
WO/2023/280144A1 |
Provided are a fusion protein consisting of an FGF21 protein and immunoglobulin Fc or fragments thereof, and a method for treating diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver, non-alcoholic steatohepati...
|
|
WO/2023/279212A1 |
The present application discloses neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof that are effective against several SARS-CoV-2 variants. Pharmaceutical compositions comprising the antibodies or antigen-bindi...
|
|
WO/2023/282315A1 |
Provided is a method for the secretory production of an unnatural-amino-acid-containing protein. In the present invention, coryneform bacteria that have a genetic construct for secretory expression of an unnatural-amino-acid-containing p...
|
|
WO/2023/280042A1 |
The present invention relates to an anti-CD24 antibody or an antigen-binding fragment thereof capable of binding CD24 and/or capable of exerting an anti-tumor effect by means of an antibody Fc fragment and the use thereof.
|
|
WO/2023/279771A1 |
Provided in the present invention are an anti-multiple-sclerosis recombinant protein, and a preparation method therefor. The recombinant protein of the present invention comprises Mycobacterium tuberculosis heat shock protein 65 and six ...
|
|
WO/2023/272924A1 |
Provided are a novel fully human antibody for human B7H3, a chimeric antigen receptor, and uses thereof; also provided are a novel fully human anti-human B7H3 antibody, a chimeric antigen receptor containing the antibody, and genetically...
|
|
WO/2023/274104A1 |
Provided is an intein C-terminal sequence variant, wherein compared with an amino acid sequence as shown in SEQ ID NO. 1, the intein C-terminal sequence variant contains at least one mutation positioned at amino acid positions selected f...
|
|
WO/2023/276395A1 |
To simultaneously improve therapeutic efficacy and reduce side effects in an adoptive immunotherapy, the present invention provides a novel technique for enhancing functions such as proliferation ability of immune cells to be used in the...
|
|
WO/2023/273958A1 |
Provided is a hexavalent trispecific antibody. The hexavalent trispecific antibody is a dimer formed by two monomers; each monomer comprises a heavy chain, a first light chain, and a second light chain; from N terminal to C terminal, the...
|
|
WO/2023/273914A1 |
Provided in the present invention is an antibody against human CD3 or an antigen-binding fragment thereof; also provided are a nucleic acid molecule encoding the antibody, an expression vector expressing the antibody and a host cell, as ...
|
|
WO/2023/274382A1 |
A multi-targets synthetic TCR and antigen/antibody receptor (M-STA/AR), a T cell containing the M-STA/AR, and use of the M-STA/AR and the T cell.
|
|
WO/2023/274352A1 |
A binding molecule comprising a binding domain that binds to an antigen expressed on an activated hepatic stellate cells (HSC), and a functional domain that is capable of enhancing an antibody effector function such as antibody-dependent...
|
|
WO/2023/274384A1 |
Provided is an antigen-binding polypeptide specifically binding to B7H3. The antigen-binding polypeptide contains at least one complementarity determining region (CDR) of an antibody heavy chain variable region (VH), wherein the VH conta...
|
|
WO/2022/266778A1 |
BCMA T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds BCMA, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypept...
|
|
WO/2022/267097A1 |
A polypeptide targeting integrin α6 and the use thereof. The polypeptide has a sequence motif of RWYD, and is stronger in affinity, wherein the equilibrium dissociation constant KD reaches the level of nM, and the affinity is greatly im...
|
|
WO/2022/268983A2 |
The present invention inter alia relates to immunocytokines involving IL-15 superagonists (based on IL-15 and the sushi domain of IL-15Rα) and an antibody. The invention also provides nucleic acids, vectors, methods and medical uses.
|
|
WO/2022/271466A1 |
Described herein are polypeptides comprising an IGF 2 amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Mutations within t...
|
|
WO/2022/271536A1 |
The disclosure relates to covalent protein dimers of MYC, MAX, and Omomyc; pharmaceutical compositions comprising the covalent protein dimers; methods of making the covalent protein dimers; and methods of treating disorders associated wi...
|
|
WO/2022/268162A1 |
A treatment method for administration of immune effector cells to an individual suffering from or suspected of suffering from a CLD18 positive biliary tract tumor, comprising administrating immune effector cells that specifically recogni...
|
|
WO/2022/267942A1 |
Polypeptides having specific spatial structures and an application thereof in preparing iPSCs are provided, amino acid sequences of the polypeptides having the specific spatial structures being as shown in SEQ ID NOs. 1-5. Also provided ...
|
|
WO/2022/270588A1 |
In this fusion protein, ferredoxin-thioredoxin reductase and thioredoxin are fused via a linker peptide. The linker peptide includes glycine (G) and serine (S).
|
|
WO/2022/268991A1 |
The present invention provides interleukin 15 (IL-15) variants comprising amino acid substitutions for improved homogeneity as well as conjugates and fusion proteins comprising such IL-15 variants. Further, nucleic acids, vectors and hos...
|
|
WO/2022/269007A1 |
The present invention refers to a method for expanding activated adult stem cells or tumor stem cells and/or for maintaining an activated adult stem cell or tumor stem cell culture in vitro in a stem state and/or preventing its senescenc...
|
|
WO/2022/262832A1 |
Provided is a bispecific fusion protein, comprising a first binding domain and a second binding domain. The first binding domain comprises an antibody specifically binding to PD-L1, the antibody comprises two antibody light chains and tw...
|
|
WO/2022/262142A1 |
Provided is a recombinant RBD trimer protein capable of simultaneously generating cross neutralization activity aiming at multiple SARS-CoV-2 epidemic strains. The trimer protein is composed of subunits of three novel coronavirus S prote...
|
|
WO/2022/266399A1 |
Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived exosomes including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers through an antibody fragment scFV region, bifunctional or ByTE antibodies, by...
|
|
WO/2022/262765A1 |
A preparation and an application of a chimeric antigen receptor immune cell constructed on the basis of granzyme B. Specifically, a granzyme B (GrB)-based modified chimeric antigen receptor (CAR), the CAR containing an extracellular bind...
|
|
WO/2022/262496A1 |
The immunoconjugate molecules contain an interleukin-2 (IL-2) polypeptide and a masking moiety capable of inhibiting and activating the IL-2 activity under suitable conditions. Methods for producing the immunoconjugate molecules. The the...
|
|
WO/2022/265091A1 |
A purpose of the present invention is to provide an epitope peptide of human α-synuclein having high antibody inducibility against not only α-synuclein monomers but also α-synuclein oligomers, and a pharmaceutical composition includin...
|
|
WO/2022/262859A1 |
The present invention relates to an anti-human MSLN humanized antibody and the use thereof. In particular, the present invention relates to an anti-human MSLN humanized antibody, a nucleic acid encoding same, a method for preparing an an...
|
